Effect of Food and Age on the Pharmacokinetics of LY03017

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Alzheimer's Disease PsychosisParkinson Disease PsychosisNegative Symptoms of Schizophrenia

Interventions

DRUG

LY03017

single dose，administered orally for each period

DRUG

LY03017

single dose，administered orally

Trial Locations (1)

Shanghai Mental Health Center, Shanghai

All Listed Sponsors

lead

Luye Pharma Group Ltd.

INDUSTRY